RCM
BIOL

Rotella Capital Management’s Biolase, Inc. BIOL Stock Holding History

Rotella Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1
Closed -$27K – 624
2014
Q4 		$27K Buy
+1
New +$31.3K 0.02% 332

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Rotella Capital Management's BIOL Position: Q1 2015 in Review

Rotella Capital Management sold out of Biolase, Inc. (BIOL) in Q1 2015, closing a stake of 1 share — an estimated $27K sold.

Rotella Capital Management first reported a position in BIOL in Q4 2014 and held it in 1 quarter. The position peaked at $27K in Q4 2014. 36 funds tracked by Wall St. Rank hold BIOL as of Q1 2015.

  • Rotella Capital Management reported no remaining Biolase, Inc. position as of Q1 2015 after selling out during the quarter.
  • Rotella Capital Management sold 1 Biolase, Inc. share in Q1 2015, an estimated $27K.
  • Rotella Capital Management first reported a position in Biolase, Inc. in Q4 2014 and held it in 1 quarter.
  • Rotella Capital Management's Biolase, Inc. position peaked at $27K in Q4 2014.
  • 36 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2015.

Based on Rotella Capital Management's 13F filing for Q1 2015, filed 4 May 2015.